Medline 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Medline's 3rd quarter 2026 net sales increased 10% year over year to $7.9 billion, driven almost entirely by organic growth with minimal foreign currency impact.
- Medline brand net sales grew 7% to $3.6 billion, with Surgical Solutions up 8% to $1.7 billion, Frontline Care up 4% to $1.7 billion, and Lab and Diagnostics up 14% to $272 million.
- Supply Chain Solutions net sales increased 14% to $4.2 billion, driven by new customer implementations and growth with existing customers.
- U.S. acute care net sales grew 12% to $5.5 billion, U.S. non-acute care net sales grew 6% to $1.9 billion, and international net sales grew 8% to $518 million.
- Adjusted EBITDA increased 12% year over year to $1 billion, and adjusted EBITDA margin rose 10 basis points to 12.2%; results included an $81 million benefit from IEPA tariff refunds and associated customer repayments.
- Higher sales volumes were partly offset by higher operating costs, inflation-related cost of goods sold, and customer, channel, and segment mix.
- Supply Chain Solutions adjusted EBITDA margin was 4.4% in the quarter, reflecting customer mix and increased operating expenses.
- Tracy, California distribution center fire-related costs reduced net income by $80 million in the 3rd quarter and were excluded from adjusted EBITDA; Medline had received and recognized $100 million of insurance recovery through the 3rd quarter.
- Medline generated $1.8 billion of free cash flow in the first 9 months of the year; CapEx was $348 million, cash and short-term investments were $3.6 billion, and net leverage improved to 2.5 times from 2.9 times last quarter.
- Medline authorized a $1 billion share repurchase program and made a $750 million term loan prepayment in October.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to Medline's third quarter 2026 results conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Karen King, Global Head of Investor Relations.
Welcome to Medline's third quarter 2026 earnings conference call. This morning, we issued our earnings release and shared supplemental materials. Joining me on today's call are Jim Boyle, our Chief Executive Officer, and Mike Drazin, our Chief Financial Officer. During today's call, we may make forward-looking statements regarding our expectations for the future, including our business plans, strategy, and investments, and expected timing and impact. These statements are based on how we see things today, and actual results may differ materially due to risks and uncertainties. Please see the cautionary statements and risk factors contained in our earnings release, which accompanies these remarks, as well as our most recent 10-K and other SEC filings for more information regarding these risks and uncertainties. We will also reference non-GAAP financial measures, which exclude certain items from our financial results calculated in accordance with GAAP.
You can find a discussion of our non-GAAP financial measures and reconciliations to the comparable GAAP measures in the earnings release and the disclosures and non-GAAP reconciliations that accompany these remarks, which are available at our website at ir.medline.com under Quarterly Results. With that, I will now turn the call over to our CEO, Jim Boyle.
Thank you, Karen, and good morning, everyone. We executed well during the quarter, delivering strong, broad-based growth. Third quarter net sales increased 10% as compared to the third quarter of 2025. Net sales for Medline Brand grew 7% with growth across all product categories, and Supply Chain Solutions grew 14%, driven by new customer implementations and growth within existing customers. Adjusted EBITDA rose 12% to $1 billion. Strong sales growth and tariff refunds drove the increase, partially offset by higher operating expenses, higher COGS from inflation, and customer mix. With that backdrop, I would like to highlight five areas that demonstrate the progress we are making across the business. First, customer signings. We had another strong quarter of total new customer signings across multiple channels, including an agreement to supply physician offices for one of the largest health systems in the U.S., and a contract to serve the hospital labs of a large Midwest nonprofit integrated delivery network.
Based on our results so far this year and the strength of our pipeline, we're confident in reaching our full-year goal of $1 billion. Second, Canada. We're very encouraged by the progress we're making in Canada with our first Prime Vendor partnership with Mohawk Medbuy. We're now live at five hospitals, delivering strong service levels and receiving positive customer feedback. We expect to finish the rollout by the end of the first quarter of 2027, marking an important step in bringing our Prime Vendor model to Canada. Third, Tracy. We're nearing an important milestone in Northern California following the fire at our previous facility.
Our new distribution center in Tracy is on track to open by year-end, adding capacity to serve customers across the region. The facility will include our largest single AutoStore installation to date, automating the picking of less-than-case items, which we expect to improve throughput and efficiency in mid-2027. Fourth, network capacity. Beyond Tracy, we're making significant investments across our distribution network. We're adding millions of square feet of distribution space at three new facilities with AutoStore automation, increasing capacity and operational flexibility across our distribution network. In March, we announced plans to construct a 1.2 million square foot distribution center in Dallas-Fort Worth. In July, we announced plans to open a new distribution center in Southern California, adding another 1 million square feet to support healthcare providers across the state.
Recently, we announced that we are building an 800,000 sq ft facility in Michigan to support customer demand in that region. Together, it will help make our supply chain more resilient and responsive. Fifth, quality. I want to provide an update on the progress we're making under our Global Quality Action Plan. Patient safety and product quality remain paramount. As part of the plan, we have engaged independent third parties to conduct assessments across our more than 30 manufacturing sites worldwide. Given the breadth of our global network, we expect these assessments to be a multi-year effort. We're also investing in people, processes, and technology to strengthen our quality systems and capabilities while continuing to remediate any impacted products. These investments, based on what we know today, are reflected in our 2026 guidance and our 2027 framework, which Mike will discuss here in a moment.
Overall, we're pleased by the momentum we're seeing and the progress we're making against our priorities. We're on track to achieve our total new customer signings goal, expand our distribution capacity, and advance our Global Quality Action Plan. At the same time, we remain focused on navigating near-term margin pressure, as Mike will discuss shortly, while continuing to invest in the capabilities to support our customers and drive long-term growth. With that, I'll turn the call over to Mike to walk through our financial performance and outlook.
Thank you, Jim, and good morning, everyone. We delivered another strong quarter with every segment and channel contributing to growth. Third quarter net sales increased 10% year over year to $7.9 billion, driven almost entirely by organic growth, with minimal impact from foreign currency. The Medline Brand segment generated third quarter net sales of $3.6 billion, an increase of 7%, with growth across all three product categories. Surgical Solutions generated net sales of $1.7 billion, up 8%. Growth was driven by surgical kitting, one of our largest product divisions, and broader demand for operating room products. We continue to gain share by expanding kits with existing customers, helping them run more efficient operating rooms, and by launching new kitting programs. Front Line Care net sales were $1.7 billion, up 4%, driven by healthy demand in exam gloves and personal care.
Lab & Diagnostics generated net sales of $272 million, up 14%, driven by growth with existing customers and new customer implementations. Many of the multi-channel agreements we signed this year include lab, contributing to this strong growth. One recent example is the acute care lab business of a large Midwest nonprofit health system that Jim mentioned earlier. The Supply Chain Solutions segment delivered third quarter net sales of $4.2 billion, up 14%, driven by new customer implementations and growth with existing customers. This growth expands our opportunity for customer conversions to Medline Brand products over time. Moving to sales by channel, U.S. acute care net sales grew 12% year over year to $5.5 billion, driven by new Prime Vendor customers and existing customer growth.
U.S. non-acute care net sales grew 6% year over year to $1.9 billion, driven by existing customers and new customer signings, primarily in physician offices, surgery centers, and post-acute care. International net sales grew 8% to $518 million, driven by volume growth in Canada and Europe. Turning to Adjusted EBITDA, third quarter was up 12% year over year to $1 billion, and margins increased 10 basis points to 12.2%. Results included an $81 million benefit from our IEEPA tariff refunds and associated customer repayments. Without giving effect to these benefits, higher sales volumes were partially offset by higher operating costs, higher COGS from inflation due to elevated oil prices, and mix. This includes customer mix of Prime Vendor relationships at lower margin, channel mix towards acute care sales, and segment mix as Supply Chain Solutions continues to outgrow the higher margin Medline Brand.
Looking at the segments, Supply Chain Solutions Adjusted EBITDA margin was 4.4% in the quarter, primarily due to the customer mix I just discussed, as well as an increase in operating expenses. We have had success winning and implementing new Prime Vendor business, and those relationships have lower initial margin due to first-year rebates. This can also apply to existing customer renewals where we believe there are additional opportunities over time for greater Medline Brand conversion. We anticipate Supply Chain Solutions margin will remain in the mid-fours the remainder of this year. Providing an update on the financial impact of the fire at our Tracy, California distribution center in June, related costs in the third quarter reduced net income by $80 million and are excluded from Adjusted EBITDA. While we expect full insurance recovery over time, we have received and recognized $100 million through the third quarter.
Moving to free cash flow and the balance sheet, we generated strong free cash flow of $1.8 billion for the first nine months of the year. This reflects net tariff benefits and favorable working capital, partially offset by investments in CapEx. CapEx for the first nine months was $348 million, reflecting investments in automation across our distribution network, construction of new distribution centers, and expansion of our Mexico kitting facility. Cash and short-term investments were $3.6 billion, and net leverage improved to 2.5 times, down from 2.9 times last quarter. Our cash generation gives us meaningful capital allocation flexibility.
Our priorities remain investing in the business to drive sustainable organic growth through operational investments, capital expenditures, and working capital, pursuing strategic bolt-on acquisitions in products, channels, and services where we can apply the Medline business model to drive attractive returns, maintaining a strong balance sheet and a disciplined approach to leverage, as demonstrated by the $750 million Term Loan prepayment we made in October, and returning capital to shareholders when supported by our cash generation, balance sheet capacity, and valuation. Our newly authorized $1 billion share repurchase program gives us flexibility to do so opportunistically. Moving to 2026 guidance, given continued strong demand and consistent commercial execution, we are raising our full year 2026 organic sales guidance for the third consecutive quarter to 10%-10.5% from 9%-10%.
As a reminder, this guidance reflects the impact of IFA tariff-related customer repayments, which reduced sales by $78 million in the first nine months. We are reaffirming our Adjusted EBITDA guidance of $3.3 billion-$3.4 billion and expect to land at approximately the midpoint. Strong sales are helping us offset cost pressures that have intensified through the year, primarily inflation tied to elevated oil prices, which has increased our estimate of Middle East conflict costs from $70 million to $80 million, and mix, as well as continued investments in our distribution network and Global Quality Action Plan. We now expect the timing of inflation to weigh more heavily in the fourth quarter than the third, as higher-cost inventory flows through the cost of goods sold.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
23 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
